Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper.
about
Patient preferences in advanced or recurrent ovarian cancer.The Aminosteroid Derivative RM-133 Shows In Vitro and In Vivo Antitumor Activity in Human Ovarian and Pancreatic CancersComparative effectiveness research in gynecologic oncology.SGO guidance document for clinical trial designs in ovarian cancer: a changing paradigm.Fifth annual workshop of cytoreductive surgery for advanced ovarian cancer and peritoneal surface malignancies.Novel therapies, including enzastaurin, in the treatment of ovarian cancer.Vintafolide (EC145) for the treatment of folate-receptor-α positive platinum-resistant ovarian cancer.Anti-angiogenic therapy versus dose-dense paclitaxel therapy for frontline treatment of epithelial ovarian cancer: review of phase III randomized clinical trials.Intermediate clinical endpoints: a bridge between progression-free survival and overall survival in ovarian cancer trials.Emerging therapies: angiogenesis inhibitors for ovarian cancer.Quality of life is significantly associated with survival in women with advanced epithelial ovarian cancer: An ancillary data analysis of the NRG Oncology/Gynecologic Oncology Group (GOG-0218) study.Patient-reported outcomes (PRO) in ovarian cancer clinical trials-lost opportunities and lessons learned.Surgical lymph node assessment in mucinous ovarian carcinoma staging: a systematic review and meta-analysis.A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer.ICG-fluorescence imaging for detection of peritoneal metastases and residual tumoral scars in locally advanced ovarian cancer: A pilot study.Comparison of first-line chemotherapy regimens for ovarian carcinosarcoma: a single institution case series and review of the literature.Ovarian cancer in 2015: Insights into strategies for optimizing ovarian cancer care.Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysis
P2860
Q27336251-FFB3479B-E8BC-4D9D-BA29-344C6B6D5F06Q28551531-0B5968AA-3331-481D-B09C-7C7F51783C82Q35793038-696EB4E1-F6F8-4879-88E2-98533EE88D56Q36424039-AE930FAC-1B8C-4032-B325-E0B2EBA19577Q37364271-70D24A9A-6893-44E6-A3BA-FCB95A5ED825Q38198095-A3B2C5DB-2FD8-4356-B642-702DD33E017DQ38205273-843F5BC8-6A02-49C7-8747-04CF8A3F5F46Q38257830-FFF18B0B-C8CA-4D2D-8992-4C7807CDDC17Q38261859-0E1D1DFE-2526-4ED9-848A-5D97010597FEQ38497958-6D2B19D4-A624-4840-825B-CDFB055C70FCQ38661788-714DF5B6-30A3-442E-B966-2C2BE6E17446Q38872226-EA8419EA-341A-43CB-855C-8928D2C91E6DQ38904850-A9EF5EF0-07B7-4B95-A9F3-7EA8C04C714AQ47861842-5C5DECBC-0EA4-492E-B89F-FE622A294052Q48272417-041EE6C7-150D-4F4C-B610-7CD63E5C742EQ50094270-445C27C2-0B8B-42C5-BE35-077F6E07F360Q53224888-62D5F204-3DE8-4FC5-8A59-59A8AD5CE6F4Q58799481-0B07A907-A962-4E9A-BEA4-36E4E532AF42
P2860
Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper.
@ast
Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper.
@en
type
label
Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper.
@ast
Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper.
@en
prefLabel
Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper.
@ast
Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper.
@en
P2093
P2860
P1433
P1476
Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper.
@en
P2093
Bradley J Monk
Deborah K Armstrong
J Tate Thigpen
Jeannine A Villella
Mark F Brady
Mark H Einstein
Robert L Coleman
Robert S Mannel
Ronald D Alvarez
Sharee A Umpierre
P2860
P356
10.1016/J.YGYNO.2013.11.008
P407
P577
2013-11-15T00:00:00Z